OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
The launch is yet another first of its kind innovation in India
Dr. Muffazal Lakdawala performs the largest series of complete robotic gastric bypass surgery in India
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Enabling a new era in minimally invasive obesity treatment across Europe
Subscribe To Our Newsletter & Stay Updated
